today announced that its collaboration with the Institute for Systems Biology and the Swiss Federal Institute of Technology for the mapping of the complete human being proteome by mass spectrometry is definitely entering its second phase. 20, the ETH and ISB Zurich announced completion of the first stage of this two-year project, including generating gold-standard reference mass spectra for every of 20,300 genes presently annotated as protein-encoding in the human genome. The project is likely to fuel research benefits in biomarker validation and discovery, the search for protein-based diagnostic tests, individualized medicine and human wellness monitoring.Further information on the clinical study is available at Zinthionein is Adeona’s single dose, proprietary, gastro-retentive, sustained-launch, oral formulation of zinc cysteine that is intended to have better bioavailability of zinc compared to the FDA-approved preparation of inorganic zinc acetate. In addition, Zinthionein is made to be better tolerated with considerably less gastrointestinal side effects than the FDA-approved preparation of inorganic zinc acetate. Adeona expects that Component 2 of the CopperProof-2 study ought to be completed by the final end of March 2011.